文献速递血栓与止血

GARFIELD-VTE患者急性静脉血栓栓塞抗凝治疗模式

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
PubMed 文献 · J Thromb Haemost · 2019-07-23

GARFIELD-VTE注册研究纳入9647例起始抗凝治疗的静脉血栓栓塞患者,49.6%使用直接口服抗凝药(DOAC)±肠外抗凝,33.0%使用维生素K拮抗剂(VKA)±肠外抗凝,17.4%仅用肠外抗凝。抗凝模式因患者人群、地理区域和血栓部位而异,指南未总被遵循。

要点

  • DOAC±肠外抗凝占49.6%,VKA±肠外抗凝占33.0%,仅肠外抗凝占17.4%。
  • 疑似VTE者67.7%仅用肠外抗凝单药治疗。
  • 深静脉血栓患者单用DOAC比例高于肺栓塞±深静脉血栓(36.2% vs 25.9%)。

核心结论

  • 抗凝治疗模式因患者人群、地理区域和VTE部位而异,抗凝治疗指南未总被遵循。

研究设计与样本

  • GARFIELD-VTE为观察性注册研究,纳入9647例起始抗凝治疗的VTE患者,按肠外抗凝、肠外抗凝转VKA、仅VKA、肠外抗凝转DOAC和仅DOAC分类。

主要发现

  • 4781例(49.6%)接受DOAC±肠外抗凝,3187例(33.0%)接受VKA±肠外抗凝,1679例(17.4%)仅接受肠外抗凝。
  • 利伐沙班是最常用的DOAC(79.4%)。
  • DOAC使用率:北美/澳大利亚58.1%,欧洲52.2%,亚洲47.6%,拉丁美洲29.7%,中东/南非32.5%。
  • 疑似VTE患者中67.7%仅接受肠外抗凝单药治疗。
  • 活动性癌症患者中58.9%仅接受肠外抗凝,25.5%接受DOAC±肠外抗凝,12.8%接受肠外抗凝+VKA;妊娠患者中46.5%仅接受肠外抗凝单药,34.0%接受VKA±肠外抗凝,19.5%接受DOAC±肠外抗凝。

关键数值与推荐

  • 深静脉血栓患者单用DOAC比例36.2%,肺栓塞±深静脉血栓患者25.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Parenteral anticoagulants and vitamin K antagonists (VKAs) have constituted the cornerstone of venous thromboembolism (VTE) treatment. Meanwhile, direct oral anticoagulants (DOACs) provide physicians with an alternative. The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE observes real-world treatment practices. OBJECTIVES: Describe initial anticoagulation (AC) treatment patterns in VTE patients who received parenteral AC, VKAs, and/or DOACs within ±30 days of diagnosis. METHODS: VTE patients were categorized into parenteral AC only, parenteral AC with transition to VKA, VKA only, parenteral AC with transition to DOAC, and DOAC only. RESULTS: A total of 9647 patients were initiated on AC treatment alone. 4781 (49.6%) patients received DOACs ± parenteral ACs; 3187 (33.0%), VKA ± parenteral ACs; and 1679 (17.4%) parenteral ACs alone. Rivaroxaban was the most frequently used DOAC (79.4%). DOACs were more frequently used in North America/Australia (58.1%), Europe (52.2%), and Asia (47.6%) than in Latin America (29.7%) and the Middle East/South Africa (32.5%). In patients with suspected VTE, most received parenteral AC monotherapy (67.7%). Patients with deep vein thrombosis were more likely to receive DOACs alone than those with pulmonary embolism with or without deep vein thrombosis (36.2% vs 25.9%). Active cancer patients received parenteral AC alone (58.9%), with 25.5% receiving DOAC ± parenteral AC and 12.8% parenteral AC and VKA. A total of 46.5% of pregnant patients received parenteral AC monotherapy, 34.0% were treated with VKA ± parenteral AC, and 19.5% received a DOAC (± parenteral AC). CONCLUSION: AC treatment patterns vary by patient population, geographic region and site of VTE. Guidelines for AC therapy are not always adhered to.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Haas S, Ageno W, Weitz JI, et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost. 2019. PMID: 31220403. doi:10.1111/jth.14548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。